ITI-111

**ITI-111** is a nasal spray formulation of **midazolam**, a short-acting benzodiazepine, developed as an orphan drug for the management of **acute repetitive seizures (ARS)** in patients with epilepsy. It provides a non-invasive alternative to intramuscular or rectal administration, addressing unmet needs in seizure cluster treatment where no new FDA-approved products had emerged in nearly 15 years prior to its development. Originally developed by **Ikano Therapeutics**, rights were acquired by **Upsher-Smith Laboratories** (later **Proximagen**) for further clinical advancement.

Brand names

Nayzilam

Other names

USL-261USL261USL 261NAYZILAM CIVmidazolam nasal spray